CMS has issued a product-specific code for Harrow's new ocular surface anesthesia Iheezo, enabling a more efficient billing process for healthcare providers.
Iheezo, a topical anesthetic approved by the FDA in Sept. 2022, is the first ocular anesthetic approved for use in 14 years, according to a Feb. 2 press release.
Iheezo does not require patients to receive any supplemental anesthesia to undergo surgical procedures.
By receiving a product-specific CMS code, ophthalmologists, optometrists and retina specialists will be able to easily bill for Iheezo, creating greater accessibility for the product.